Process for preparing an a2a-adenosine receptor agonist and its polymorphs
AssigneeGilead Sciences, Inc.
InventorsJeff Zablocki, Elfatih Elzein, Robert Seemayer, Travis Lemons
Life of this patent
Estimating the term…
Abstract
Disclosed is a synthesis suitable for large scale manufacture of an A2A-adenosine receptor agonist, and also relates to polymorphs of that compound, and to methods of isolating a specific polymorph.
Claims13
1-20. (canceled)
A crystalline monohydrate form of the compound (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-methylcarboxamide which is substantially free of 2-hydrazinoadenosine.
A pharmaceutical composition prepared from a crystalline monohydrate form of the compound (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-methylcarboxamide by adding at least one pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.